|
|
 Previous Article | Table of Contents | Next Article 
CD44 Is Involved in Tumor Angiogenesis; an Activation Antigen on Human Endothelial Cells
Arjan W. Griffioen,
Marieke J.H. Coenen,
Cora A. Damen,
Sandra M.M. Hellwig,
David H.J. van Weering,
Wim Vooys,
Geert H. Blijham, and
Gerard Groenewegen
From the Department of Internal Medicine and Medical Oncology, Laboratory for Angiogenesis Research, University Hospital Utrecht; the Department of Immunohaematology, University Hospital Utrecht; the Department of Physiological Chemistry, Utrecht University, Utrecht, The Netherlands.
CD44 is described to be an activation molecule in a number of different cell types. We investigated the role of CD44 on human endothelial cells (EC) and in tumor angiogenesis. Using flow cytometry we showed that EC from the vasculature of human solid tumors display an enhanced expression of CD44 as compared to EC from normal tissue. This finding was confirmed by immunohistochemical studies on frozen tissue sections. Because tumors are dependent on angiogenesis, the role of angiogenic stimuli in the enhanced CD44 expression was investigated. We found that basic fibroblast growth factor (bFGF ) and vascular endothelial growth factor were able to efficiently upregulate CD44 expression on cultured human EC. The upregulation reached maximal levels after treatment for 3 days with 10 ng/mL bFGF. The physiological impact of this upregulation was shown by the enhanced binding of EC to hyaluronate after pretreatment with bFGF. In a next set of studies that were designed to unravel the regulation of CD44 expression on EC we concluded that CD44 is an activation antigen on human EC since (1) human umbilical vein derived endothelial cells, which in vivo do not express CD44, begin to express CD44 when plated and cultured, (2) CD44 expression is enhanced after subculture of confluent cultures, (3) CD44 is predominantly expressed on the BrdU incorporating subset of cultured EC. The specific expression of CD44 on activated and tumor EC prompted us to study the usefulness of CD44 as an endothelial target for therapy with immunotoxins. In vitro experiments showed that EC are efficiently killed after targeting immunotoxin to CD44.
Blood, Vol. 90 No. 3 (August 1), 1997:
pp. 1150-1159
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
V. L. Thijssen, S. Hulsmans, and A. W. Griffioen
The Galectin Profile of the Endothelium: Altered Expression and Localization in Activated and Tumor Endothelial Cells
Am. J. Pathol.,
February 1, 2008;
172(2):
545 - 553.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Baronas-Lowell, J. L. Lauer-Fields, J. A. Borgia, G. F. Sferrazza, M. Al-Ghoul, D. Minond, and G. B. Fields
Differential Modulation of Human Melanoma Cell Metalloproteinase Expression by {alpha}2{beta}1 Integrin and CD44 Triple-helical Ligands Derived from Type IV Collagen
J. Biol. Chem.,
October 15, 2004;
279(42):
43503 - 43513.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Hibino, M. Shibuya, J. A. Engbring, M. Mochizuki, M. Nomizu, and H. K. Kleinman
Identification of an Active Site on the Laminin {alpha}5 Chain Globular Domain That Binds to CD44 and Inhibits Malignancy
Cancer Res.,
July 15, 2004;
64(14):
4810 - 4816.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. E. Nisato, J. A. Harrison, R. Buser, L. Orci, C. Rinsch, R. Montesano, P. Dupraz, and M. S. Pepper
Generation and Characterization of Telomerase-Transfected Human Lymphatic Endothelial Cells with an Extended Life Span
Am. J. Pathol.,
July 1, 2004;
165(1):
11 - 24.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Yan, Y. Lin, D. Yang, Y. Shen, M. Yuan, Z. Zhang, P. Li, H. Xia, L. Li, D. Luo, et al.
A novel anti-CD146 monoclonal antibody, AA98, inhibits angiogenesis and tumor growth
Blood,
July 1, 2003;
102(1):
184 - 191.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Liu, R. K. Lapcevich, C. B. Underhill, Z. Han, F. Gao, G. Swartz, S. M. Plum, L. Zhang, and S. J. Green
Metastatin: A Hyaluronan-binding Complex from Cartilage That Inhibits Tumor Growth
Cancer Res.,
February 1, 2001;
61(3):
1022 - 1028.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. W. Griffioen and G. Molema
Angiogenesis: Potentials for Pharmacologic Intervention in the Treatment of Cancer, Cardiovascular Diseases, and Chronic Inflammation
Pharmacol. Rev.,
June 1, 2000;
52(2):
237 - 268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. M. Peterson, Q. Yu, I. Stamenkovic, and B. P. Toole
Perturbation of Hyaluronan Interactions by Soluble CD44 Inhibits Growth of Murine Mammary Carcinoma Cells in Ascites
Am. J. Pathol.,
June 1, 2000;
156(6):
2159 - 2167.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Nandi, P. Estess, and M. H. Siegelman
Hyaluronan Anchoring and Regulation on the Surface of Vascular Endothelial Cells Is Mediated through the Functionally Active Form of CD44
J. Biol. Chem.,
May 12, 2000;
275(20):
14939 - 14948.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. S. Smith, J. R. Keller, N. C. Lohrey, C. S. McCauslin, M. Ortiz, K. Cowan, and S. E. Spence
Redirected infection of directly biotinylated recombinant adenovirus vectors through cell surface receptors and antigens
PNAS,
August 3, 1999;
96(16):
8855 - 8860.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. B. Lokeshwar and M. G. Selzer
Differences in Hyaluronic Acid-mediated Functions and Signaling in Arterial, Microvessel, and Vein-derived Human Endothelial Cells
J. Biol. Chem.,
September 1, 2000;
275(36):
27641 - 27649.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
